Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Respiratory Disease Testing Market $4.2 Billion by 2031

The global market for respiratory disease testing projected to reach $4.2 billion by 2031, steadily growing at a CAGR of 4.1% over the forecast period, driven by increasing prevalence of chronic respiratory disorders, growing geriatric population, and technological developments.

Global Respiratory Disease Testing Market

According to WHO, hundreds of millions of people of all ages, in all countries of the world, are affected by preventable chronic respiratory diseases.

  • More than 50% of them live in low and middle-income countries or deprived populations. The prevalence of preventable chronic respiratory diseases is increasing everywhere and in particular among children and elderly people.
    • It is currently estimated that more than 1 billion people suffer from chronic respiratory conditions causing an immense worldwide health burden that is measured in the trillions of dollars per year.
      • With an addressable target market of $25 billion spent globally on respiratory diagnostic procedures each year, technology has enormous scope for financial success as well as life changing advancement for medicine.
    • The most common of these afflictions are upper respiratory infections (URI). Children experience six to nine URI per year, which decreases to two to four URI per year in adolescents and adults. Lower respiratory infections (LRI) occur less frequently, but at a much greater cost.
      • In recent years, significant advances in the laboratory diagnostics available to detect respiratory viral infections have been achieved. As new diagnostic methods become widely available, it is increasingly important to develop guidelines for laboratory testing when viral illness is suspected.

Pulmonary function tests are used to measure the lungs’ capacity to hold air, to move air in and out, and to exchange oxygen and carbon dioxide.

  • The main clinical roles of respiratory function tests include diagnosis, assessment of severity, monitoring treatment and evaluation of prognosis.
    • These tests are better at detecting the general type and severity of lung disorders.
  • Other tests, including chest imaging, bronchoscopy, and thoracoscopy determine the specific cause of a lung disorders, such as asthma and emphysema. 
  • Blood gas tests to evaluate oxygen and carbon dioxide levels, lung or pulmonary function tests (PFTs) to help diagnose and monitor lung function, and chest x-rays and or CT (computed tomography) scans for lung structure.

The global respiratory disease testing market report estimates the market size ($million 2021 to 2031), market share, growth trends and forecast (CAGR% 2024 to 2031).

The global market for respiratory disease testing segmented by diagnostic test (blood gas test, imaging test, lung volume test, peak flow test, spirometry test, complete blood count test, and comprehensive metabolic panel test), end user (clinical laboratories, hospitals and physician office), and geography.

  • Based on the diagnostic tests, the imaging test segment accounted for the largest share of the total respiratory disease testing market, attributed to increasing demand, where these are considered as first line of diagnosis for respiratory diseases (e.g. X-ray) in developed as well as developing countries.
    • X-ray is the most commonly used in hospitals and diagnostic centers.
    • Other commonly used respiratory imaging tests include computerized tomography (CT) scan, positron emission tomography (PET) scan, magnetic resonance imaging (MRI) scan, and ultrasound scanning.
  • However, the spirometry tests segment for diagnosis of respiratory problems such as bronchitis, asthma, emphysema, and severity of the lung disease as well as monitoring treatment effectiveness expected to witness the fastest growth rate throughout the forecast period.
    • Spirometry is one of the most commonly used approaches to test pulmonary function. Spirometers are classified into closed-circuit and open-circuit spirometers.
      • Spirometry has proved to be a crucial tool in diagnosing lung disease, monitoring patients for their pulmonary function, and assessing their fitness for various procedures. For example, the standard respiratory function test for case detection of chronic obstructive pulmonary disease (COPD) is spirometry.
    • The factors driving the market growth include accurate and effective diagnostic results within shorter time span compared to other commercially available lung function testing equipment, and its common use at physician offices and clinical laboratories.

The global respiratory disease testing market research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

  • Geographically, the North America region dominated the total respiratory disease testing market, owing to increasing prevalence of respiratory diseases, rising popularity of portable devices, and growing preference for home healthcare devices and services.
    • Chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), interstitial lung disease and pulmonary sarcoidosis, asthma, and pneumoconiosis, are responsible for substantial health and financial burden in the United States each year.
      • For example, 6.7% of all deaths were due to chronic respiratory diseases, which were the fifth leading cause of death and the 8th leading cause of health burden overall as measured by disability-adjusted life-years.
  • However, the Asia Pacific region expected to register the fastest growth rate during the forecast period, due to high unmet needs, untapped opportunities, improving healthcare infrastructure, increasing public awareness, and favorable government initiatives in the emerging economies.

The global respiratory diagnostics market research report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent acquisitions and alliances.

  • Some of the respiratory diagnostic tests offered by key players in the market include GE Healthcare (Discovery XR656 Plus), Perkin Elmer, Inc. (XRD a-Si), Philips Healthcare (Mobile C-Arm with Flat Detector), SDI Diagnostics (Astra100 Spirometer), Smiths Medical (SPECTRO2 Pulse Oximeter), Cosmed (Spiropalm), Olympus America (BF-190 Bronchoscopes), and PENTAX Medical (V Series Fiber Bronchoscopes).

Major competitors operating in the global respiratory diagnostics market and included in this report are Becton, Dickinson and Company (CareFusion Corp.), Carestream Health, Inc., COSMED, Futuremed America, Inc., GE Healthcare, MGC Diagnostics Corporation (Caire, Inc.), ndd Medical Technologies, Inc., Nihon Kohden Corporation, PerkinElmer, Inc., Philips Healthcare, SDI Diagnostics, Siemens Healthineers AG, and ICU Medical, Inc. (Smiths Medical, Inc.).

  • Diagnostic Test
    • Blood Gas Test
    • Imaging Test
    • Lung Volume Test
    • Peak Flow Test
    • Spirometry Test
    • Other Tests (Complete Blood Count, Comprehensive Metabolic Panel, etc.)
  • End User
    • Clinical Laboratories
    • Hospitals
    • Physician Offices
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Becton, Dickinson and Company (CareFusion Corp.)
    • Carestream Health, Inc.
    • COSMED srl
    • Futuremed America, Inc.
    • GE Healthcare
    • MGC Diagnostics Corporation (Caire, Inc.)
    • ndd Medical Technologies, Inc.
    • Nihon Kohden Corporation
    • PerkinElmer, Inc.
    • Philips Healthcare
    • SDI Diagnostics
    • Siemens Healthineers AG
    • ICU Medical, Inc. (Smiths Medical, Inc.)

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com